Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Non-Current Liabilities (2016 - 2025)

Amicus Therapeutics' Total Non-Current Liabilities history spans 16 years, with the latest figure at $671.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 13.63% year-over-year to $671.4 million, compared with a TTM value of $671.4 million through Dec 2025, up 13.63%, and an annual FY2025 reading of $671.4 million, up 13.63% over the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $671.4 million at Amicus Therapeutics, up from $638.4 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $671.4 million in Q4 2025, with the low at $532.8 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $596.4 million, with a median of $595.3 million recorded in 2024.
  • Year-over-year, Total Non-Current Liabilities soared 72.59% in 2021 and then decreased 4.33% in 2024.
  • Tracing FOLD's Total Non-Current Liabilities over 5 years: stood at $577.4 million in 2021, then rose by 0.39% to $579.7 million in 2022, then rose by 6.54% to $617.6 million in 2023, then fell by 4.33% to $590.9 million in 2024, then increased by 13.63% to $671.4 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Total Non-Current Liabilities are $671.4 million (Q4 2025), $638.4 million (Q3 2025), and $602.4 million (Q2 2025).